Covid-19 Aşıları

Sharma O, Sultan AA, Ding H, Triggle CR. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Frontiers in Immunology. 2020. doi:10.3389/fimmu.2020.585354

Tang D, Comish P, Kang R. The hallmarks of COVID-19 disease. PLOS Pathogens. 2020. p. e1008536. doi:10.1371/journal.ppat.1008536

Graham BS. Rapid COVID-19 vaccine development. Science. 2020. pp. 945–946. doi:10.1126/science.abb8923

Chavarria-Miró G, Anfruns-Estrada E, Guix S, Paraira M, Galofré B, Sáanchez G, et al. Sentinel surveillance of SARS-CoV-2 in wastewater anticipates the occurrence of COVID-19 cases. doi:10.1101/2020.06.13.20129627

Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, et al. Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation. bioRxiv. 2020. doi:10.1101/2020.02.11.944462

Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020;34: 101623.

Spiess B. Faculty Opinions recommendation of Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature. 2020. doi:10.3410/f.737258313.793572876

Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. Journal of Travel Medicine. 2020. doi:10.1093/jtm/taaa021

Özdoğan M. Yeni koronavirüs için sürü bağışıklığı nedir? Bir hayalin peşinde miyiz? In: Prof. Dr. Mustafa ÖZDOĞAN [Internet]. 28 Oct 2020 [cited 19 Jan 2021]. Available: https://www.drozdogan.com/yeni-koronavirus-icin-suru-bagisikligi-nedir-bir-hayalin-pesinde-miyiz/

Jung F, Krieger V, Hufert FT, Küpper J-H. Herd immunity or suppression strategy to combat COVID-19. Clin Hemorheol Microcirc. 2020;75: 13–17.

[No title]. [cited 31 Jan 2021]. Available: http://www.cocukenfeksiyondergisi.org/upload/documents/2020-01/2020-14-1-055-056.pdf

Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020;181: 1489–1501.e15.

Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, et al. Immunology of COVID-19: Current State of the Science. Immunity. 2020;52: 910–941.

Liu W, Fontanet A, Zhang P-H, Zhan L, Xin Z-T, Baril L, et al. Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome. J Infect Dis. 2006;193: 792–795.

Leslie M. T cells found in COVID-19 patients “bode well” for long-term immunity. Science. 2020. doi:10.1126/science.abc8120

Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;584: 457–462.

Wu F, Liu M, Wang A, Lu L, Wang Q, Gu C, et al. Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China. JAMA Intern Med. 2020;180: 1356–1362.

Akey AM, O’Neil-Smith K. Kick COVID-19 to the Curb. FIRRIMupTM Doctors’; 2020.

Udupa DN, Seetharam DRN, Mukhopadhyay DC. COVID-19: A Multidimensional Response. Manipal Universal Press; 2020.

Callaway E. Russia’s fast-track coronavirus vaccine draws outrage over safety. Nature. 2020. pp. 334–335. doi:10.1038/d41586-020-02386-2

Sharma O, Sultan AA, Ding H, Triggle CR. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Front Immunol. 2020;11: 585354.

Tse LV, Meganck RM, Graham RL, Baric RS. The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses. Front Microbiol. 2020;11: 658.

Website. [cited 20 Jan 2021]. Available: https://www.who.int/news-room/q-a-detail/vaccines-and-immunization-what-is-vaccination?adgroupsurvey={adgroupsurvey}&gclid=CjwKCAiAo5qABhBdEiwAOtGmbsDYZA_XBw5Kf94TlIyeTedNypSk5cXGNaE0Buswn5uXS-kdJ9LCpBoCya4QAvD_BwE

Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586: 516–527.

A Dose of Realism on a COVID-19 Vaccine Strategy. 22 Oct 2020 [cited 19 Jan 2021]. Available: https://www.chathamhouse.org/2020/10/dose-realism-covid-19-vaccine-strategy

Zimmer C, Corum J, Wee S-L. Coronavirus Vaccine Tracker. The New York Times. 10 Jun 2020. Available: https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html. Accessed 19 Jan 2021.

Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, et al. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. JAMA. 2020;324: 951–960.

Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart SP, et al. Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report. doi:10.1101/2020.06.30.20142570

Website. [cited 31 Dec 2020]. Available: Safety Tolerability Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19. (2020). Available online at: https://clinicaltrials.gov/ct2/show/NCT04447781

Website. [cited 31 Dec 2020]. Available: INOVIO, COVID-19 için INO-4800 Aşısı İçin Pozitif Ara Aşama 1 Verilerini Açıkladı. (2020). Çevrimiçi olarak şu adresten ulaşılabilir: http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-Announces-Positive-Interim-Phase-1Data-For-INO-4800-Vaccine-for- COVID-19 / default.aspx

Kaur SP, Gupta V. COVID-19 Vaccine: A comprehensive status report. Virus Res. 2020;288: 198114.

Zhu F-C, Guan X-H, Li Y-H, Huang J-Y, Jiang T, Hou L-H, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396: 479–488.

Zhu F-C, Li Y-H, Guan X-H, Hou L-H, Wang W-J, Li J-X, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395: 1845–1854.

Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396: 467–478.

Thomas SJ, Yoon I-K. A review of Dengvaxia®: development to deployment. Hum Vaccin Immunother. 2019;15: 2295–2314.

Roberts M. South Africa coronavirus variant: What is the risk? In: BBC News [Internet]. 8 Jan 2021 [cited 21 Jan 2021]. Available: https://www.bbc.com/news/health-55534727

COVID-19 Aşıları Hakkında Merak Edilenler - Bayındır Sağlık Grubu. [cited 19 Jan 2021]. Available: https://www.bayindirhastanesi.com.tr/blog/covid-19-asilari-hakkinda-merak-edilenler-541

Deutsche Welle (www. dw.com). Officials warn of fake COVID-19 vaccines. Deutsche Welle (www.dw.com); [cited 20 Jan 2021]. Available: https://www.dw.com/en/officials-warn-of-fake-covid-19-vaccines/a-56123830

Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine — United States, December 2020. MMWR Surveill Summ. 2020;69: 1922.

Norway: Deaths after virus jab may be from side effects. [cited 20 Jan 2021]. Available: https://www.aa.com.tr/en/europe/norway-deaths-after-virus-jab-may-be-from-side-effects/2111033